| Literature DB >> 29284445 |
Monica Michelotti1, Dirk F de Korne2,3,4,5, Jennifer S Weizer6, Paul P Lee6, Declan Flanagan7, Simon P Kelly8, Anne Odergren9, Sukhpal S Sandhu10, Charity Wai11, Niek Klazinga12, Aravind Haripriya13, Joshua D Stein6, Melanie Hingorani7.
Abstract
BACKGROUND: To determine alignment of proposed international standard outcomes sets for ophthalmic conditions to metrics currently reported by eye hospitals.Entities:
Keywords: Benchmarking; Measurement; Outcomes; Quality improvement
Mesh:
Year: 2017 PMID: 29284445 PMCID: PMC5747118 DOI: 10.1186/s12886-017-0667-0
Source DB: PubMed Journal: BMC Ophthalmol ISSN: 1471-2415 Impact factor: 2.209
Comparison of ICHOM outcome measures for cataract surgery and reported measures in study hospitals
| Item | Proposed ICHOM Measure | Reported Measure in Study Hospitals | Number of Hospitals Reporting | Reported Value | |
|---|---|---|---|---|---|
| Intraoperative | Complications | Capsule problems | Posterior capsule rupture | 6/8 | 0.64–2.11% |
| Dropped nucleus or lens fragment into vitreous | Retained lens matter | 1/8 | 0.21% | ||
| Other | Intraoperative complications | 1/8 | 1.87% | ||
| Zonular dialysis | 1/8 | 0.11% | |||
| Choroidal hemorrhage | 1/8 | 0.11% | |||
| Postoperative | Visual acuity | Post-operative visual acuity | BCVA 20/40 or better at 4–6 weeks, all cases | 2/8 | 91% |
| BCVA 20/40 or better at 4–6 weeks, excluding co pathology | 3/8 | 87–100% | |||
| 1–14 letters improvement ETDRS VA score | 1/8 | ≈ 52% | |||
| ≥ 15 letters improvement ETDRS VA score | 1/8 | ≈ 42% | |||
| Refractive error | Post-operative refractive error | Final spherical equivalent within 1 D of target | 5/8 | 85–97% | |
| Patient-reported visual function | Rasch-calibrated score from Catquest 9SF or other Rasch-calibrated PROM | NA | 0/8 | NA | |
| Complications | Return to operating theater | Unplanned reoperation within 30 days of surgery | 4/8 | 1.1–1.52% | |
| Endophthalmitis rate | Endophthalmitis rate | 6/8 | 0.0–0.07% | ||
| Persistent corneal edema | NA | 0/8 | NA | ||
| Other (any postoperative complication within 3 months requiring treatment or compromising outcome) | Postoperative complications | 1/8 | 0.36% | ||
| Unplanned vitrectomy | 4/8 | 0.48–1.93% | |||
| Iris trauma | 1/8 | 0.32% |
ETDRS Early Treatment Diabetic Retinopathy Study, BCVA best corrected visual acuity, D Diopter, VA visual acuity
Comparison of ICHOM outcome measures for macular degeneration and reported measures in study hospitals
| Item | Propose ICHOM Measure | Reported measure in study hospitals | Number of hospitals reporting | Target | Reported value | |
|---|---|---|---|---|---|---|
| Visual functioning and vison-related quality of life | Distance visual acuity | Distance visual acuity (best of uncorrected, corrected, or pinhole) in the affected eye. | Gain VA (15 ETDRS letters) after injections for macular degeneration | 1/8 | > 20% | 20.7% |
| Visual stability (loss < 15 ETDRS letters) after injections for macular degeneration | 1/8 | > 80% | 90.25% | |||
| Mobility and independence | Impact of vision impairment questionnaire | NA | 0/8 | None | NA | |
| Emotional well-being | Impact of vision impairment questionnaire | NA | 0/8 | None | NA | |
| Reading and accessing information | Impact of vision impairment questionnaire | NA | 0/8 | None | NA | |
| Disutility of care | Number of treatments | Documentation of individual treatments received for macular degeneration | Appointment access and check in (% best response) | 1/8 | None | ≈ 63% |
| Clinic wait times and comfort (% best response) | 1/8 | None | ≈ 45% | |||
| Complications of treatment | Endophthalmitis: severe intraocular inflammation within 3 months of last intraocular treatment | Endophthalmitis after anti-VEGF intravitreal injections | 5/8 | None or 0.2–1.9%a 0.05% (MARINA) | 0–0.18% | |
| Disease control | Presence of fluid, edema, or hemorrhage | Presence of intraretinal or subretinal fluid or hemorrhage that is attributable to activity of the neovascular lesion | NA | 0/8 | None | NA |
ETDRS Early Treatment Diabetic Retinopathy Study, RD retinal detachment, VEGF vascular endothelial growth factor, PVR proliferative vitreo-retinopathy
aBhavsar et al. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required. Arch Ophthalmol 2009; 127(12): 1581–1583